On September 17, 2026, CMBI Private Equity Series SPC disposed of 999,500 H shares of BIOCYTOGEN-B off-exchange at an average of HKD 59.6951 per share, involving about HKD 59.67 million. The transaction was an off-exchange cash consideration trade, not matched on the SEHK open market.
Prior to the disposal, CMBI Private Equity Series SPC's long position in BIOCYTOGEN-B was 9.76 million shares, representing 8.81%; following the disposal, the holding changed to 8.76 million shares, with the long position ratio falling to 7.91%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments